Lead Exposure Is Associated with Decreased Serum Paraoxonase 1 (PON1) Activity and Genotypes

Lead exposure causes cardiac and vascular damage in experimental animals. However, there is considerable debate regarding the causal relationship between lead exposure and cardiovascular dysfunction in humans. Paraoxonase 1 (PON1), a high-density lipoprotein-associated antioxidant enzyme, is capable of hydrolyzing oxidized lipids and thus protects against atherosclerosis. Previous studies have shown that lead and several other metal ions are able to inhibit PON1 activity in vitro. To investigate whether lead exposure has influence on serum PON1 activity, we conducted a cross-sectional study of workers from a lead battery manufactory and lead recycling plant. Blood samples were analyzed for whole-blood lead levels, serum PON1 activity, and three common PON1 polymorphisms (Q192R, L55M, -108C/T). The mean blood lead level (+/-SD) of this cohort was 27.1+/-15 microg/dL. Multiple linear regression analysis showed that blood lead levels were significantly associated with decreased serum PON1 activity (p<0.001) in lead workers. This negative correlation was more evident for workers who carry the R192 allele, which has been suggested to be a risk factor for coronary heart disease. Taken together, our results suggest that the decrease in serum PON1 activity due to lead exposure may render individuals more susceptible to atherosclerosis, particularly subjects who are homozygous for the R192 allele.

[1]  S. Shima,et al.  Serum lipid peroxide level and blood superoxide dismutase activity in workers with occupational exposure to lead , 1985, International archives of occupational and environmental health.

[2]  G. Jarvik,et al.  Polymorphisms in the human paraoxonase (PON1) promoter. , 2001, Pharmacogenetics.

[3]  D. Shih,et al.  Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis , 1998, Nature.

[4]  Yan Shen,et al.  Extensive Association Analysis Between Polymorphisms of PON Gene Cluster With Coronary Heart Disease in Chinese Han Population , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[5]  P. Durrington,et al.  Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification , 1998, FEBS letters.

[6]  Elizabeth Selvin,et al.  Lead, Cadmium, Smoking, and Increased Risk of Peripheral Arterial Disease , 2004, Circulation.

[7]  D. Shih,et al.  Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice. , 2003, Free radical biology & medicine.

[8]  J. Marrugat,et al.  Effect of physical activity on lipid levels in a population‐based sample of men with and without the Arg192 variant of the human paraoxonase gene , 2000, Genetic epidemiology.

[9]  J. Bollinger,et al.  Inhibition of human serum arylesterase by metal chlorides. , 2003, Journal of inorganic biochemistry.

[10]  A. Motulsky,et al.  Spectrophotometric assays for the enzymatic hydrolysis of the active metabolites of chlorpyrifos and parathion by plasma paraoxonase/arylesterase. , 1989, Analytical biochemistry.

[11]  C. Furlong,et al.  Determination of paraoxonase (PON1) status requires more than genotyping. , 1999, Pharmacogenetics.

[12]  R. Elosua,et al.  Interaction between the Gln-Arg 192 variants of the paraoxonase gene and oleic acid intake as a determinant of high-density lipoprotein cholesterol and paraoxonase activity. , 2001, European journal of pharmacology.

[13]  M. Jelen,et al.  Lipid abnormalities in rats given small doses of lead , 2005, Archives of Toxicology.

[14]  E. Rubin,et al.  Paraoxonase 1 overexpression in mice and its effect on high-density lipoproteins. , 2002, Biochemical and biophysical research communications.

[15]  J. Gerberding,et al.  Preventing lead poisoning in young children. , 1992, Kansas medicine : the journal of the Kansas Medical Society.

[16]  G. Schellenberg,et al.  Paraoxonase ( PON 1 ) Phenotype Is a Better Predictor of Vascular Disease Than Is PON 1 192 or PON 1 55 Genotype , 2000 .

[17]  J. Staessen,et al.  An epidemiological re-appraisal of the association between blood pressure and blood lead: a meta-analysis , 2002, Journal of Human Hypertension.

[18]  P. McElduff,et al.  Low Paraoxonase Activity Predicts Coronary Events in the Caerphilly Prospective Study , 2003, Circulation.

[19]  J. Danesh,et al.  Four paraoxonase gene polymorphisms in 11 212 cases of coronary heart disease and 12 786 controls: meta-analysis of 43 studies , 2004, The Lancet.

[20]  F. Gil,et al.  Inhibition of paraoxonase activity in human liver microsomes by exposure to EDTA, metals and mercurials. , 1997, Chemico-biological interactions.

[21]  Herbert L. Needleman,et al.  Preventing lead poisoning in young children , 1978 .

[22]  P. Froom,et al.  The association between occupational lead exposure and serum cholesterol and lipoprotein levels. , 1999, American journal of public health.

[23]  A. Tward,et al.  Decreased Atherosclerotic Lesion Formation in Human Serum Paraoxonase Transgenic Mice , 2002, Circulation.

[24]  P. Durrington,et al.  Paraoxonase Status in Coronary Heart Disease: Are Activity and Concentration More Important Than Genotype? , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[25]  Ellen Silbergeld,et al.  Blood lead levels and mortality. , 2002, Archives of internal medicine.

[26]  B. La Du,et al.  Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[27]  V. Trimble,et al.  Structure and Evolution of the Sun , 2004 .

[28]  G. Schellenberg,et al.  Paraoxonase (PON1) Phenotype Is a Better Predictor of Vascular Disease Than Is PON1192 or PON155 Genotype , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[29]  D. Adler,et al.  The molecular basis of the human serum paraoxonase activity polymorphism , 1993, Nature Genetics.

[30]  A. Motulsky,et al.  Role of genetic polymorphism of human plasma paraoxonase/arylesterase in hydrolysis of the insecticide metabolites chlorpyrifos oxon and paraoxon. , 1988, American journal of human genetics.

[31]  Dan S. Tawfik,et al.  Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes , 2004, Nature Structural &Molecular Biology.